+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Candidiasis - Pipeline Review, H2 2020

  • ID: 5146933
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 225 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Acea Biotech Inc
  • Cellix Bio Pvt Ltd
  • Helix BioMedix Inc
  • Nosopharm SAS
  • Pfizer Inc
  • Scynexis Inc
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H2 2020, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews the key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 5, 3, 32, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Acea Biotech Inc
  • Cellix Bio Pvt Ltd
  • Helix BioMedix Inc
  • Nosopharm SAS
  • Pfizer Inc
  • Scynexis Inc
  • MORE
Introduction
  • Candidiasis - Overview
  • Candidiasis - Therapeutics Development
Candidiasis - Therapeutics Assessment

Candidiasis - Companies Involved in Therapeutics Development

Candidiasis - Drug Profiles

Candidiasis - Dormant Projects
  • Candidiasis - Discontinued Products
  • Candidiasis - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Candidiasis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..3), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Candidiasis - Pipeline by Acea Biotech Inc, H2 2020
  • Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2020
  • Candidiasis - Pipeline by Autoimmune Technologies LLC, H2 2020
  • Candidiasis - Pipeline by Bakker Medical Srl, H2 2020
  • Candidiasis - Dormant Projects, H2 2020
  • Candidiasis - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Candidiasis - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Candidiasis - Dormant Projects, H2 2020 (Contd..3), H2 2020
  • Candidiasis - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Candidiasis, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • Acea Biotech Inc
  • Amplyx Pharmaceuticals Inc
  • Autoimmune Technologies LLC
  • Bakker Medical Srl
  • Beta Pharma Inc
  • Biokawthar Technologies SAS
  • Biomendics LLC
  • Biosergen AS
  • Cellix Bio Pvt Ltd
  • Cidara Therapeutics Inc
  • CSA Biotechnologies LLC
  • CSPC Pharmaceutical Group Ltd
  • Destiny Pharma Plc
  • Fox Chase Chemical Diversity Center Inc
  • FUJIFILM Toyama Chemical Co Ltd
  • General Biologicals Corp
  • Grupo Ferrer Internacional SA
  • Helix BioMedix Inc
  • Hennepin Life Sciences LLC
  • iCo Therapeutics Inc
  • iNtRON Biotechnology Inc
  • Matinas BioPharma Holdings Inc
  • Mycovia Pharmaceuticals Inc
  • Mycovia Pharmaceuticals Inc
  • Nanomerics Ltd
  • Next Science Ltd
  • Nosopharm SAS
  • Novabiotics Ltd
  • NovaDigm Therapeutics Inc
  • Novartis AG
  • Oryn Therapeutics
  • Pfizer Inc
  • Profem GmbH
  • Pulmocide Ltd
  • Riptide Bioscience Inc
  • Sano Chemicals Inc
  • Scynexis Inc
  • Sealife PHARMA GMBH
  • Shaanxi Synthetic Pharmaceutical Co Ltd
  • Stadius Biopharma LLC
  • TGV Laboratories Inc
  • TGV Therapeutics
  • Toltec Pharmaceuticals LLC
  • Visterra Inc
  • Wellstat Vaccines LLC
Note: Product cover images may vary from those shown
Adroll
adroll